RT Journal Article
T1 Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
A1 Gavilá, Joaquín
A1 Oliveira, Mafalda
A1 Pascual, Tomás
A1 Perez-Garcia, Jose
A1 Gonzàlez, Xavier
A1 Canes, Jordi
A1 Paré, Laia
A1 Calvo, Isabel
A1 Ciruelos, Eva
A1 Muñoz, Montserrat
A1 Virizuela, Juan A
A1 Ruiz, Isabel
A1 Andrés, Raquel
A1 Perelló, Antonia
A1 Martínez, Jerónimo
A1 Morales, Serafín
A1 Marín-Aguilera, Mercedes
A1 Martínez, Débora
A1 Quero, Juan C
A1 Llombart-Cussac, Antonio
A1 Prat, Aleix
K1 Breast cancer
K1 HER2
K1 HER2-enriched
K1 PAM50
K1 cardiac safety
K1 intrinsic subtypes
K1 neoadjuvant
YR 2019
FD 2019-01-09
LK http://hdl.handle.net/10668/13391
UL http://hdl.handle.net/10668/13391
LA en
DS RISalud
RD Apr 10, 2025